Patents by Inventor Yubo Zhou

Yubo Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250042862
    Abstract: Disclosed are an aromatic heterocyclic compound and an application thereof. The aromatic heterocyclic compound is represented by formula I, and the compound has good LSD1 enzyme inhibitory activity, and can be used as an LSD1 inhibitor for treatment of tumors etc.
    Type: Application
    Filed: November 10, 2022
    Publication date: February 6, 2025
    Inventors: Bing XIONG, Jia LI, Tongchao LIU, Yubo ZHOU, Cong LI, Na LI, Weijuan KAN, Mingbo SU, Li SHENG, Xiaobei HU
  • Publication number: 20240360146
    Abstract: Disclosed are a Bruton's tyrosine kinase and a mutant degrader thereof; or a stereoisomer thereof, or a stereoisomer mixture thereof or a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug for treating diseases, disorders or conditions that would benefit from the degradation of the Bruton's tyrosine kinase and the mutant thereof. The compound of the present invention can degrade BTK protein, can degrade BTKC481S protein, has an anti-proliferation inhibiting effect on tumor cell strains Mino and OCI-LY10, shows good anti-tumor activity in an OCI-LY10 subcutaneous transplantation tumor model, has an inhibiting effect on B cell activation, and can be applied to B cell or plasma cell proliferative diseases and autoimmune diseases. The compound of the present invention has good oral absorption properties, and can be applied to oral treatment of human or animal B cell or plasma cell proliferative diseases and autoimmune diseases.
    Type: Application
    Filed: June 30, 2022
    Publication date: October 31, 2024
    Inventors: Xinglu ZHOU, Jia LI, Xingguo LIU, Yubo ZHOU, Miao HU, Xiaomin LUO, Jiangfeng XIE, Weijuan KAN, Mingbo SU, Yizhe WU
  • Publication number: 20240270753
    Abstract: The present invention relates to a heterocyclic compound for inhibiting SHP2 activity that is represented by formula I, a preparation method therefor and use thereof. The compound of the present invention is effective in treating a disease or disorder or condition mediated by SHP2.
    Type: Application
    Filed: March 30, 2022
    Publication date: August 15, 2024
    Inventors: Bing ZHOU, Jia LI, Yubo ZHOU, Xiangbo YANG, Bo FENG, Yaxi YANG, Xiaobei HU
  • Publication number: 20240253916
    Abstract: Disclosed are article loading and unloading equipment and an article loading and unloading system, relating to the field of logistics machinery, for improving the performance of article loading and unloading equipment. The article loading and unloading equipment comprise a base assembly, a cantilever assembly and a conveying assembly. The base assembly is configured to provide support. The cantilever assembly comprises a first bracket assembly and a first conveyor, the first bracket assembly being mounted to the base assembly; and the first conveyor being mounted to the first bracket assembly. The conveying assembly comprises a second bracket assembly, a second conveyor and a suction cup assembly, the second bracket assembly being mounted to the first bracket assembly, the second conveyor being mounted to the second bracket assembly, and the suction cup assembly being rotatably mounted to the second bracket assembly; and the suction cup assembly being configured to adsorb an article to the second conveyor.
    Type: Application
    Filed: March 26, 2021
    Publication date: August 1, 2024
    Inventors: Xianwang WANG, Weiquan HE, Jian ZHANG, Yafang ZHANG, Yubo ZHOU
  • Publication number: 20240219207
    Abstract: In a first aspect, the present invention relates to a system for sensing a displacement (d) along a direction y of a magnet relative to a sensor, comprising: (i) a sensor for measuring a first magnetic field component Bu along a direction u, and a second magnetic field component Bz along a direction z, substantially orthogonal to u and y; and (ii) a magnet above the sensor in the z-direction, the magnet having a magnetization direction substantially perpendicular to a major surface of the magnet, substantially perpendicular to the z-direction and different from the y-direction.
    Type: Application
    Filed: December 26, 2023
    Publication date: July 4, 2024
    Inventor: Yubo ZHOU
  • Patent number: 11974999
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: January 1, 2021
    Date of Patent: May 7, 2024
    Assignees: Suzhou Baijibugong Pharmaceutical Technology Co., Ltd.
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Patent number: 11969964
    Abstract: This disclosure provides a method for manufacturing a silver-plated reflecting film. The method includes following steps: (1) manufacturing a reflecting polyester film layer; (2) coating a silver-plated layer on one surface of the reflecting polyester film layer by a vacuum sliver plating method, wherein the vacuum silver plating methods comprises a vacuum evaporation plating method or a vacuum sputtering silver plating method; and (3) applying a protection layer film on the silver-plated layer and obtaining the silver-plated reflecting film.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: April 30, 2024
    Assignee: NINGBO SOLARTRON TECHNOLOGY CO., LTD.
    Inventors: Yadong Jin, Yubo Zhou
  • Patent number: 11873292
    Abstract: The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: January 16, 2024
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Hong Liu, Jia Li, Wei Zhu, Yubo Zhou, Jiang Wang, Mingbo Su, Shuni Wang, Wei Xu, Chunpu Li, Weijuan Kan, Hualiang Jiang, Kaixian Chen
  • Publication number: 20230295144
    Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Application
    Filed: January 24, 2023
    Publication date: September 21, 2023
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • Patent number: 11591325
    Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: February 28, 2023
    Assignees: ZHEJIANG UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • Patent number: 11554118
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: January 17, 2023
    Assignees: SUZHOU BAIJIBUGONG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Publication number: 20220041578
    Abstract: The present invention relates to an isoindoline compound as represented by general formula (I) and used as a CRBN regulator, and a preparation method, a pharmaceutical composition, and an application of the isoindoline compound. Specifically, a class of polysubstituted isoindoline compound provided in the present invention, as a class of CRL4CRBN E3 ubiquitin ligase regulator having a novel structure, has good anti-tumor activity and immunoregulatory activity, and can be used for preparing drugs for treating diseases associated with a CRL4CRBN E3 ubiquitin ligase.
    Type: Application
    Filed: December 6, 2019
    Publication date: February 10, 2022
    Inventors: Xiaohua CHEN, Jia LI, Yu CHENG, Yubo ZHOU, Huijun NIE, Yujie WANG, Andi GUO, Weijuan KAN
  • Publication number: 20220041576
    Abstract: The present invention relates to a polysubstituted isoindoline compound as shown in general formula (I), and a preparation method, a pharmaceutical composition and the use thereof. In particular, the polysubstituted isoindoline compound is provided in the present invention as a class of novel CRL4CRBN E3 ubiquitin ligase modulators in structure, wherein same has a stronger antitumor activity and antitumor spectrum, and can be used to prepare drugs for treating CRL4CRBN E3 ligase-related diseases.
    Type: Application
    Filed: September 30, 2019
    Publication date: February 10, 2022
    Inventors: Xiaohua CHEN, Jia LI, Yu CHENG, Yubo ZHOU, Huijun NIE, Yujie WANG, Hongtao TIAN, Weijuan KAN, Tian MI, Xiaobei HU, Binshan ZHOU, Kenian YAN, Gaoya XU, Yuhua ZHONG, Lei FENG
  • Publication number: 20220017505
    Abstract: Provided by the present disclosure are an amino quinazolinone and amino isoquinolone derivatives. It is verified by numerous experiments that the compounds provided by the present disclosure have good inhibiting effects on PI3K? and PI3K?, most of the compounds have prominent inhibiting effect on PI3K?, and show strong growth inhibiting effect on PIK3CA mutant tumor cells such as human breast cancer cell strain (MCF7). Therefore, the amino quinazolinone and amino isoquinolone derivatives according to the present disclosure can be applied in the preparation of anti-tumor and anti-inflammatory medicines, and can be used as PI3K? inhibitors in the preparation of medicines for treatment of human or animal cell proliferation related tumors, the medicines comprising the derivatives any one or more of pharmaceutically acceptable salts and solvates thereof as well as pharmaceutically acceptable carriers.
    Type: Application
    Filed: June 25, 2021
    Publication date: January 20, 2022
    Inventors: Rong SHENG, Jia LI, Dongyan GU, Yubo ZHOU, Jun WEI, Mengmeng ZHANG, Yongzhou HU, Kaixiang ZHANG, Jieyu LIU, Weijuan KAN
  • Publication number: 20210284625
    Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Application
    Filed: November 8, 2017
    Publication date: September 16, 2021
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • Publication number: 20210282064
    Abstract: In wireless communication systems and methods for high-speed mobility deployments, a mobility status of a communication device can be determined. For example, the speed at which the communication device is traveling can be determined (e.g. such as communication devices traveling on a high-speed transportation (HST) system). HST networks can be prioritized based on the determined mobility status of the communication device when performing a fallback communication and/or when returning from the fallback communication.
    Type: Application
    Filed: June 30, 2017
    Publication date: September 9, 2021
    Inventors: Jun Wang, Jingqian Wang, Donghui Guo, Weijie Sun, Jiapeng Li, Pengbo Du, Yan Lu, Xiongjun Huang, Yucheng Dai, Xiaolei Tang, Yubo Zhou
  • Publication number: 20210196179
    Abstract: Disclosed is an electrocardiograph (ECG) lead wire. The left electrode (120) and the right electrode (130) of the ECG lead wire are stacked and enclose an accommodation hole (101) for an electrode contact to pass through. At least one of the left electrode (120) and the right electrode (130) is made of an elastic material and/or is driven by an elastic member, so that the left electrode (120) and the right electrode (130) can move relative to each other under the action of an external force to widen the accommodation hole (101), and can move relative to each other under an elastic action force to narrow the accommodation hole (101). Since the size of the accommodation hole (101) can change, the electrode holder can be adapted to electrode contacts of various sizes on the market and makes same be firmly connected, thereby ensuring the stability and reliability of signal transmission.
    Type: Application
    Filed: September 12, 2018
    Publication date: July 1, 2021
    Applicant: Ningbo Xinwell Medical Technology Co., Ltd
    Inventors: Yubo ZHOU, Jiewei YU
  • Publication number: 20210121458
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: January 1, 2021
    Publication date: April 29, 2021
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Publication number: 20210107903
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: March 21, 2018
    Publication date: April 15, 2021
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Patent number: 10933063
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: March 2, 2021
    Assignees: Suzhou Baijibugong Pharmaceutical Technology Co., Ltd.
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao